Summit Therapeutics: HARMONi‑GI1 Hype vs. Real‑World Results, Investor Warnings
Summit Therapeutics’ HARMONi‑GI1 claims face scrutiny: no long‑term data, regulatory hurdles, and a shaky US launch plan leave investors cautious.
- SUMMIT THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read